Zobrazeno 1 - 10
of 19
pro vyhledávání: '"M. Patricia Ball"'
Autor:
Michael S. Kraus, James M. Gold, Deanna M. Barch, Trina M. Walker, Charlotte A. Chun, Robert W. Buchanan, John G. Csernansky, Donald C. Goff, Michael F. Green, L. Fredrik Jarskog, Daniel C. Javitt, David Kimhy, Jeffrey A. Lieberman, Joseph P. McEvoy, Raquelle I. Mesholam-Gately, Larry J. Seidman, M. Patricia Ball, Robert S. Kern, Robert P. McMahon, James Robinson, Stephen R. Marder, Richard S.E. Keefe
Publikováno v:
Schizophrenia Research: Cognition, Vol 19, Iss , Pp - (2020)
In comparison to batteries of standard neuropsychological tests, cognitive neuroscience tests may offer a more specific assessment of discrete neurobiological processes that may be aberrant in schizophrenia. However, more information regarding psycho
Externí odkaz:
https://doaj.org/article/f20147e5a0884772be0a6d0500251fdb
Autor:
Matcheri S. Keshavan, L. Fredrik Jarskog, Cameron S. Carter, Margaret A. Peykamian, Michael F. Green, Larry J. Seidman, Alan Breier, Martin T. Lowy, John G. Csernansky, Jeffrey A. Lieberman, Joshua T. Kantrowitz, Donald C. Goff, Stephen R. Marder, Richard S.E. Keefe, M. Patricia Ball, Robert P. McMahon, Joseph P. Horrigan, Robert W. Buchanan, Marc Laurelle, Paul Maruff, Richard Grove
Publikováno v:
Schizophrenia Research. 164:136-142
This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf45603c5fc671ab113c8cd5ece30aa5
https://doi.org/10.1016/j.schres.2015.01.041
https://doi.org/10.1016/j.schres.2015.01.041
Autor:
John G. Csernansky, Robert S. Kern, Karen S. Nolan, S Deanna, David Kimhy, Robert W. Buchanan, James M. Gold, Michael F. Green, Larry J. Seidman, Robert P. McMahon, Jeffrey A. Lieberman, Daniel C. Javitt, M. Patricia Ball, Richard S.E. Keefe, Fred Jarskog, Joseph P. McEvoy, Donald C. Goff, Stephen R. Marder, James Robinson
Publikováno v:
Schizophrenia Research. 136:25-31
Background Cognitive dysfunction is a key predictor of functional disability in schizophrenia. Davunetide (AL-108, NAP) is an intranasally administered peptide currently being developed for treatment of Alzheimer's disease and related disorders. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e87e6f26560b31697c60b027a333e056
https://doi.org/10.1016/j.schres.2011.11.001
https://doi.org/10.1016/j.schres.2011.11.001
Autor:
Robert W. Buchanan, James M. Gold, Alison S. Buchholz, Robert P. McMahon, A. Eden Evins, Elaine Weiner, M. Patricia Ball
Publikováno v:
The Journal of Clinical Psychiatry. 73:95-102
OBJECTIVE: To clarify the efficacy and tolerability of bupropion sustained release (SR) for the treatment of cigarette smoking in people with schizophrenia. METHOD: The first study is a double-blind, placebo-controlled clinical trial with 32 outpatie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da36c843a12c69e46cedc0ec61737d95
https://doi.org/10.4088/jcp.10m06143gre
https://doi.org/10.4088/jcp.10m06143gre
Autor:
Robert W. Buchanan, Monica C. Mann-Wrobel, Melanie E. Bennett, Elaine Weiner, M. Patricia Ball
Publikováno v:
Schizophrenia Research. 126:277-283
Objective The present study sought to better understand the relationships among smoking history, motivation to change, and smoking cessation outcomes in people with schizophrenia who smoke. Method We examined smoking and quit history, negative conseq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1ed55b1240834b357731cc5681458c1
https://doi.org/10.1016/j.schres.2010.10.030
https://doi.org/10.1016/j.schres.2010.10.030
Autor:
Deanna L. Kelly, Ikwunga Wonodi, M. Patricia Ball, Robert W. Buchanan, Robert P. McMahon, James M. Gold, Robert R. Conley, Elaine Weiner, Stephanie Feldman
Publikováno v:
Neuropsychopharmacology. 35:2274-2283
The large numbers of partial clozapine responders represent a major therapeutic challenge. Unfortunately, there are no clear data to support how best to treat these patients. This study examines the efficacy and safety of adjunctive risperidone in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98d29800ebd4409fb68aba91b58f5b51
https://doi.org/10.1038/npp.2010.101
https://doi.org/10.1038/npp.2010.101
Autor:
Robert W. Buchanan, Deanna L. Kelly, Robert R. Conley, Douglas L. Boggs, Dwight Dickinson, Matthew W. Nelson, M. Patricia Ball, James M. Gold, Fang Liu, Stephanie Feldman, Robert P. McMahon
Publikováno v:
The Journal of Clinical Psychiatry. 70:518-525
Background Currently available antipsychotic medications offer only modest, if any, effects on cognitive performance in people with schizophrenia. Treatments that would improve these impairments could lead to better functional outcomes. Atomoxetine i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35c9d4934aff1e3d2e6053c6b413cab6
https://doi.org/10.4088/jcp.08m04358
https://doi.org/10.4088/jcp.08m04358
Autor:
James M. Gold, M.S.W. Stephanie Feldman, Robert W. Buchanan, R.N. M. Patricia Ball, Robert P. McMahon, Dwight Dickinson, Robert R. Conley
Publikováno v:
American Journal of Psychiatry. 165:82-89
People with schizophrenia are characterized by a broad range of cognitive impairments. Despite appropriate treatment with conventional or second-generation antipsychotics, they continue to exhibit pronounced impairments. The current study was designe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09beedf0f9ec738b680d59eb67054f79
https://doi.org/10.1176/appi.ajp.2007.07050724
https://doi.org/10.1176/appi.ajp.2007.07050724
Autor:
L Fredrik, Jarskog, Martin T, Lowy, Richard A, Grove, Richard S E, Keefe, Joseph P, Horrigan, M Patricia, Ball, Alan, Breier, Robert W, Buchanan, Cameron S, Carter, John G, Csernansky, Donald C, Goff, Michael F, Green, Joshua T, Kantrowitz, Matcheri S, Keshavan, Marc, Laurelle, Jeffrey A, Lieberman, Stephen R, Marder, Paul, Maruff, Robert P, McMahon, Larry J, Seidman, Margaret A, Peykamian
Publikováno v:
Schizophrenia research. 164(1-3)
This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63aee1f616ea869813d07a6ffc2518a6
https://pubmed.ncbi.nlm.nih.gov/25728831
https://pubmed.ncbi.nlm.nih.gov/25728831
Publikováno v:
Psychiatric Services. 52:967-969
This study evaluated the effectiveness of a Weight Watchers program for patients with schizophrenia who had olanzapine-related weight gain and ascertained whether the severity of patients' psychiatric symptoms was correlated with the patients' succes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe27187ebf012aaa35d1dc93bde197ce
https://doi.org/10.1176/appi.ps.52.7.967
https://doi.org/10.1176/appi.ps.52.7.967